MicroStrategy
MSTR
NVIDIA
NVDA
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
US Stock MarketDetailed Quotes
BRNS Barinthus Biotherapeutics
- 1.110
- +0.090+8.82%
Close Dec 20 16:00 ET
- 1.110
- 0.0000.00%
Post 17:37 ET
44.65MMarket Cap-0.74P/E (TTM)
1.114High1.020Low36.40KVolume1.050Open1.020Pre Close38.61KTurnover0.13%Turnover RatioLossP/E (Static)40.23MShares4.15952wk High0.28P/B31.27MFloat Cap0.80152wk Low--Dividend TTM28.17MShs Float17.990Historical High--Div YieldTTM9.26%Amplitude0.801Historical Low1.060Avg Price1Lot Size
Barinthus Biotherapeutics News
H.C. Wainwright Maintains Barinthus Biotherapeutics(BRNS.US) With Buy Rating, Maintains Target Price $5
Promising Clinical Trials and Potential Functional Cure Drive Buy Rating for Barinthus Biotherapeutics
Barinthus Biotherapeutics Analyst Ratings
H.C. Wainwright Maintains Barinthus Biotherapeutics(BRNS.US) With Buy Rating, Maintains Target Price $5
H.C. Wainwright Maintains Barinthus Biotherapeutics(BRNS.US) With Buy Rating, Maintains Target Price $5
Buy Rating Affirmed on Barinthus Biotherapeutics Amid Promising Clinical Trials and Therapeutic Advances
H.C. Wainwright Maintains Barinthus Biotherapeutics(BRNS.US) With Buy Rating, Maintains Target Price $5
Barclays Maintains Barinthus Biotherapeutics(BRNS.US) With Buy Rating, Maintains Target Price $3
Barclays Remains a Buy on Barinthus Biotherapeutics (BRNS)
Barinthus Biotherapeutics Price Target Cut to $9.50/Share From $11.00 by Alliance Global Partners
Barinthus Biotherapeutics Analyst Ratings
A. G. P. Maintains Barinthus Biotherapeutics(BRNS.US) With Buy Rating, Cuts Target Price to $9.5
HC Wainwright & Co. Reiterates Buy on Barinthus Biotherapeutics, Maintains $5 Price Target
Buy Rating Reaffirmed for Barinthus Biotherapeutics Amid Promising Clinical Advancements
Barinthus Biotherapeutics Analyst Ratings
Barinthus Biotherapeutics Analyst Ratings
HC Wainwright & Co. : The Barinthus Biotherapeutics (BRNS.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $8.00.
Barinthus Biotherapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Barinthus Biotherapeutics, Maintains $8 Price Target
Buy Rating for Barinthus Biotherapeutics Backed by Strong Financials and Promising Clinical Trials
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.